About: Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice
Creator	Mangalam, Ashutosh Hoffman, Carol Kochetkova, Irina Maddaloni, Massimo Pascual, David
topic	covid:6d5600b0c8725f08c005efaaf90fe3668aef1c65#this
Source	PMC
abstract	IL-35, a relatively newly discovered cytokine belonging to the larger IL-12 family, shows unique anti-inflammatory properties, believed to be associated with dedicated receptors and signaling pathways. IL-35 plays a pivotal role in the development and the function of both regulatory B (Bregs) and T cells (Tregs). In order to further its therapeutic potential, a dairy Lactococcus lactis strain was engineered to express murine IL-35 (LL-IL35), and this recombinant strain was applied to suppress collagen-induced arthritis (CIA). Oral administration of LL-IL35 effectively reduced the incidence and disease severity of CIA. When administered therapeutically, LL-IL35 abruptly halted CIA progression with no increase in disease severity by reducing neutrophil influx into the joints. LL-IL35 treatment reduced IFN-γ and IL-17 3.7- and 8.5-fold, respectively, and increased IL-10 production compared to diseased mice. Foxp3(+) and Foxp3(−) CD39(+) CD4(+) T cells were previously shown to be the Tregs responsible for conferring protection against CIA. Inquiry into their induction revealed that both CCR6(+) and CCR6(−) Foxp3(+or−) CD39(+) CD4(+) T cells act as the source of the IL-10 induced by LL-IL35. Thus, this study demonstrates the feasibility and benefits of engineered probiotics for treating autoimmune diseases.
has issue date	2018-11-20(xsd:dateTime)
bibo:doi	10.3389/fimmu.2018.02691
bibo:pmid	30515168
has license	cc-by
sha1sum (hex)	6d5600b0c8725f08c005efaaf90fe3668aef1c65
schema:url	https://doi.org/10.3389/fimmu.2018.02691
resource representing a document's title	Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice
has PubMed Central identifier	PMC6255909
has PubMed identifier	30515168
schema:publication	Front Immunol
resource representing a document's body	covid:6d5600b0c8725f08c005efaaf90fe3668aef1c65#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/6d5600b0c8725f08c005efaaf90fe3668aef1c65
is schema:about of	named entity 'IL-10' named entity 'ROLE' named entity 'DEDICATED' named entity 'STRAIN' named entity 'COLLAGEN-INDUCED ARTHRITIS' named entity 'POTENTIAL' named entity 'RECEPTORS' named entity 'IFN' named entity 'DAIRY' named entity 'RESPONSIBLE' named entity 'ADMINISTERED' named entity 'INDUCED' named entity 'DISEASED' named entity 'INCIDENCE' named entity 'CYTOKINE ' named entity 'REDUCING' named entity 'AUTOIMMUNE DISEASES' named entity 'IL-35' named entity 'MICE' named entity 'PROPERTIES' named entity 'ACT' named entity 'TO EXPRESS' named entity 'THERAPEUTIC' named entity 'ANTI-INFLAMMATORY' named entity 'express' named entity 'IL-17' named entity 'plays' named entity 'discovered' named entity 'LACTOCOCCUS LACTIS' named entity 'IL-35' named entity 'FOXP3' named entity 'SUPPRESS' named entity 'LARGER' named entity 'UNIQUE' named entity 'JOINTS' named entity 'PROGRESSION' named entity 'ASSOCIATED WITH' named entity 'TREATMENT' named entity 'PLAYS' named entity 'BENEFITS' named entity 'CD4' named entity 'IL-10 PRODUCTION' named entity 'FOLD' named entity 'REGULATORY' named entity 'INQUIRY' named entity 'MURINE' named entity 'INDUCTION' named entity 'IL-17' named entity 'DEVELOPMENT' named entity 'INCREASED' named entity 'DELIVERY' named entity 'MICE' named entity 'AMELIORATES' named entity 'ORAL ADMINISTRATION' named entity 'LACTOCOCCUS LACTIS' named entity 'ENGINEERED' named entity 'NEUTROPHIL' named entity 'ITS' named entity 'PROBIOTICS' named entity 'FAMILY' named entity 'IL-12' named entity 'APPLIED' named entity 'DISEASE SEVERITY' named entity 'RECOMBINANT' named entity 'FUNCTION' named entity 'REVEALED' named entity 'PROTECTION' named entity 'T CELLS' named entity 'CIA' named entity 'FEASIBILITY' named entity 'NEWLY DISCOVERED' named entity 'STUDY' named entity 'COLLAGEN-INDUCED ARTHRITIS' named entity '8.5' named entity 'SIGNALING PATHWAYS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software